New monthly weight loss shot shows promise in Mid-Stage trial
NCT ID NCT06973720
First seen Jun 24, 2026 · Last updated Jun 24, 2026
Summary
This study tests a new drug called MET097, given as a shot, to help people with obesity or overweight lose weight. After 12 weekly doses, participants switch to monthly shots for up to 64 weeks. The trial compares four different dose schedules against a placebo to see which works best and is safest. About 268 people without type 2 diabetes are taking part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CenExel iResearch, LLC
Decatur, Georgia, 30030, United States
-
CenExel iResearch, LLC
Savannah, Georgia, 31405, United States
-
ForCare Clinical Research
Tampa, Florida, 33613, United States
-
Hassman Research Institute
Marlton, New Jersey, 08053, United States
-
Research Centers of America
Hollywood, Florida, 33024, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
MET097 (a weight loss drug given as a shot)
What this could lead to
If successful, this could lead to a monthly injection for weight loss, offering a more convenient option than weekly shots.
What could go wrong
This is a mid-stage trial with only 268 people, so results may not hold in larger studies. Side effects are possible, and the drug may not work for everyone.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.